Supplementary Figure 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo

Fröhlich, Lisa Marie; Niessner, Heike; Sauer, Birgit; Kämereit, Sofie; Chatziioannou, Eftychia; Riel, Simon; Sinnberg, Tobias; Schittek, Birgit

doi:10.1158/2767-9764.24089891.v1

crc-23-0101-s01.pdf (192.91 kB)

Supplementary Figure 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo

journal contribution

posted on 2023-09-06, 17:07 authored by Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, Sofie Kämereit, Eftychia Chatziioannou, Simon Riel, Tobias Sinnberg, Birgit Schittek

PARPi treatment in melanoma cells

Funding

Deutsche Forschungsgemeinschaft (DFG)

History

ARTICLE ABSTRACT

We show that MAPK inhibitor resistant melanoma cells exhibit low ATM expression increasing their sensitivity toward PARP inhibitors and that a combination of MAPK/PARP inhibitors act synthetically lethal in melanoma cells. Our study shows that PARP inhibitor treatment is a valuable therapy option for patients with melanoma, either as a single treatment or as a combination with MAPK inhibitors depending on ATM expression, which could serve as a novel biomarker for treatment response.